Volume 7, Number 1, March 2017
|Number of page(s)||5|
|Published online||03 March 2017|
Etodolac and the risk of acute pancreatitis
College of Medicine, Tzu Chi University, Hualien
2 Department of Internal Medicine, Taichung Tzu Chi General Hospital, Taichung 427, Taiwan
3 Graduate Institute of Integrated Medicine, China Medical University, Taichung 404, Taiwan
4 College of Medicine, China Medical University, Taichung 404, Taiwan
5 Department of Family Medicine, China Medical University Hospital, Taichung 404, Taiwan
6 Management Office for Health Data, China Medical University Hospital, Taichung 404, Taiwan
* Corresponding author. Department of Family Medicine, China Medical University Hospital, No. 2, Yuh-Der Road, Taichung 404, Taiwan. E-mail address: email@example.com (S.-W. Lai).
Accepted: 19 September 2016
Objective: The aim of this study was to explore the association between etodolac use and acute in Taiwan.
Design: We designed a case-control study using the database of Taiwan’s National Health Insurance.
Subjects: In all, 7577 subjects aged 20 years or older with newly diagnosed acute pancreatitis were defined as cases, and 27032 sex-matched and age-matched subjects without acute pancreatitis were defined as controls. The period considered for this study was from 1998 to 2011. For the study, never having used etodolac is defined as a subject never receiving a prescription for etodolac. Active use of etodolac is defined as a subject receiving at least 1 prescription for etodolac within 7 days of the date of their being diagnosed with acute pancreatitis. Non-active use of etodolac is defined as a subject not receiving a prescription for etodolac within 7 days but receiving at least 1 prescription for etodolac ≥ 8 days before the date of their being diagnosed with acute pancreatitis.
Main outcome measure: The association between etodolac use and acute pancreatitis was estimated by using the multivariable unconditional logistic regression model.
Results: After correcting for covariates, the adjusted odds ratio of acute pancreatitis was 3.78 for subjects with active use of etodolac (95% confidence interval 1.11, 12.9), compared with subjects who never used etodolac. The adjusted odds ratio decreased to 1.18 for subjects with non-active use of etodolac (95% confidence interval 0.38, 3.67), but that was without statistical significance.
Conclusion: There could be an association between active use of etodolac and acute pancreatitis. Clinicians should take into account the possibility of etodolac-associated acute pancreatitis when patients currently using etodolac present with acute pancreatitis with an unknown cause.
Key words: Acute pancreatitis / Etodolac
© Author(s) 2017. This article is published with open access by China Medical University
Open Access This article is distributed under terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided original author(s) and source are credited.